Dr Reddy's launches Reditux(TM) - Monoclonal Antibody Treatment for Non-Hodgkin's Lymphoma

Dr Reddy’s Laboratories (NYSE: RDY) today announced the launch of Reditux™, the Dr Reddy’s brand of rituximab, a monoclonal antibody (MAb) used in the treatment of Non-Hodgkin’s Lymphoma. The launch event was held in Hyderabad with over 100 leading oncologists attending the unveiling of the RedituxTM brand followed by a technical session on the development of the drug. Talking at the technical session Dr Anji Reddy, Chairman, Dr. Reddy’s Laboratories said "Dr. Reddy’s has always been committed to creating value by applying science to help people lead healthier lives – Reditux™ is yet another example of this commitment. This is a proud moment for the organization, to know that we have succeeded in developing this very complex molecule which will help in providing an affordable solution to patients.” The technical session detailed the approach taken by Dr. Reddy’s in developing this complex protein therapeutic including data from the clinical trial. There was also an open forum with a panel comprising the clinical trial investigators and the members of the independent Data Safety Monitoring Board (DSMB) addressing questions from the audience regarding the clinical experience with the drug. In his talk at the conclusion of the technical session, Dr. Alok Srivastava - the coordinating investigator for the trial and Professor of Medicine and Head of the Department of Haematology at Christian Medical College, Vellore - commented on the excellent pre-clinical data that had been made available to the investigators prior to the start of the clinical trial and emphasized the importance of post-marketing surveillance to monitor the safety of the product. Dr Reddy’s also launched its social initiative called "Sparsh” - an Assistance Program for cancer patients undergoing treatment - at the Reditux™ launch. Patients identified by the doctors through Sparsh would be provided Reditux™ free of cost. Talking about Sparsh, G V Prasad, the Vice Chairman & CEO, Dr Reddy’s Laboratories added, "We understand the dilemma that doctors and patients face in cancer therapy. The care is very expensive and it can be financially debilitating for most patients. This is a reality we are acutely aware of at Dr Reddy’s and the Sparsh initiative is a first step to serve the needs of the patients by increasing access and affordability of medicine. While the program is in early stages of implementation in the oncology care space; we hope to further increase the reach to other therapeutic areas in future.” Reditux™ is the second product from Dr. Reddy’s Biologics Division. There are several other products in development primarily in the areas of oncology and autoimmune diseases. Notes to the Editor: Non-Hodgkin lymphoma (NHL) describes a group of cancers arising from lymphocytes, a type of white blood cell. It is distinct from Hodgkin lymphoma in its pathologic features, epidemiology, common sites of involvement, clinical behavior, and treatment. The non-Hodgkin lymphomas are a diverse group of diseases with varying courses, treatments, and prognoses. NHL is the 6th leading cause of cancer death in the United States. Approximately 95% of cases occur in adults 40 to 70 years in age. As per Globocan 2002, in India more than 20,000 patients are diagnosed yearly with NHL. Sparsh can be accessed on www.sparshindia.com by the country’s Oncologists. Doctors will be given access to the website by the company wherein they can refer needy patients for treatment of Reditux™. Dr Reddy’s would ensure that the patients identified by the doctors through Sparsh are provided the recommended therapy free of cost. Reditux™ is approximately priced at half the originator’s price. Product availability is planned at Company’s C&F agents and at all major hospitals in the country. Disclaimer This press release includes forward-looking statements, as defined in the U.S. Private Securities Litigation Reform Act of 1995. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future. About Dr. Reddy’s Established in 1984, Dr. Reddy's Laboratories (NYSE: RDY) is an emerging global pharmaceutical company with proven research capabilities. The Company is vertically integrated with a presence across the pharmaceutical value chain. It produces finished dosage forms, active pharmaceutical ingredients and biotechnology products and markets them globally, with focus on India, US, Europe and Russia. The Company conducts research in the areas of diabetes, cardiovascular, anti-infectives, inflammation and cancer.